While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...